Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials

Gastrin has been shown to be a growth stimulant in pancreatic cancer cells. Gastrazole is a potent and selective gastrin receptor antagonist. Two randomised blinded trials were conducted to assess the effect of gastrazole in advanced pancreatic cancer. Patients with biopsy-proven, inoperable pancrea...

Descripción completa

Detalles Bibliográficos
Autores principales: Chau, I, Cunningham, D, Russell, C, Norman, A R, Kurzawinski, T, Harper, P, Harrison, P, Middleton, G, Daniels, F, Hickish, T, Prendeville, J, Ross, P J, Theis, B, Hull, R, Walker, M, Shankley, N, Kalindjian, B, Murray, G, Gillbanks, A, Black, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361246/
https://www.ncbi.nlm.nih.gov/pubmed/16622436
http://dx.doi.org/10.1038/sj.bjc.6603058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361246/
https://www.ncbi.nlm.nih.gov/pubmed/16622436
http://dx.doi.org/10.1038/sj.bjc.6603058

Ejemplares similares